Gliatilin: (Choline alfoscerate 400 mg capsules, 1,000 mg/4ml solution for injection) psychostimulant and cholinergic drug that activates the central nervous system of elderly patients, improves cognitive and memory function and brings benefit to the affective sphere and behaviour compromised by the involutional brain disease. Unlike other nootropic substances, Gliatilin exhibits a dual mechanism of action, ensuring a large supply of choline to the brain and providing glycerophosphate to restore the phospholipids in the neuronal membranes.

Dropaxin: (paroxetine hydrochloride - oral drops, 10 mg/ml solution) the first paroxetine hydrochloride available in a drop formulation; indicated in the treatment of episodes of major depression, obsessive compulsive disorder, panic disorder with or without agoraphobia, social anxiety disorder/social phobia, generalized anxiety disorder and post-traumatic stress disorder. Dropaxin combines the established efficacy of paroxetine with the dosage flexibility offered by a drop formulation, particularly important at the start and end of treatment. Betadex technology, patented by the Italfarmaco Group, also increases the stability of gastric acid and improves the absorption and bioavailability of the drug.